Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1- or SMARCA4-deficient tumors: PEPN2121.

Authors: Mary Frances Wedekind, Srivandana Akshintala, Brigitte C. Widemann, Charles Minard, Olga Militano, David Hall, Zanette Bradley, Joel M. Reid, Joseph Gerald Pressey, Elad Sharon, Jennie Haunani Foster, Elizabeth Fox, Brenda Weigel

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2695

Source: Full article

---

Abstract

TPS2695